Related Experiment Videos
Discrete monoclonal antibodies define functionally important epitopes in the CD200 molecule responsible for
Dang-Xiao Chen1, Reginald M Gorczynski
1The Toronto Hospital, University Health Network, Toronto, Canada.
Transplantation
|February 9, 2005
Summary
Monoclonal antibodies targeting the N-terminal domain of CD200 enhance immune responses by blocking immunosuppression. Antibodies targeting other regions do not affect immune cell activity, highlighting the importance of specific CD200 epitopes.
Area of Science:
- Immunology
- Molecular Biology
Background:
- CD200 fusion proteins (CD200Fc) are immunosuppressants that engage CD200 receptors (CD200R).
- Anti-CD200 monoclonal antibodies (mAbs) can boost immune activity by neutralizing endogenous CD200.
- Previous research identified critical N-terminal domains in CD200 and CD200R1 for binding and antagonism.
Purpose of the Study:
- To compare the activity of anti-CD200 mAbs against mouse and human CD200Fc.
- To correlate antibody binding to CD200 with their ability to augment immune reactivity in mixed leukocyte cultures (MLCs).
Main Methods:
- Utilized a panel of mAbs against mouse and human CD200Fc.
- Assessed antibody binding via flow cytometry (FACS) and ELISA.
- Evaluated antibody-induced immune augmentation in MLCs.
Main Results:
- mAbs targeting N-terminal epitopes augmented MLC reactivity and blocked CD200Fc-mediated immunosuppression.
- mAbs targeting C-domain epitopes bound CD200 in FACS/ELISA but did not affect MLCs.
- Antibody binding affinity did not correlate with immune-augmenting activity.
Conclusions:
- N-terminal epitopes are crucial for CD200's immunosuppressive function.
- mAbs targeting N-terminal epitopes can overcome CD200-mediated immunosuppression.
- Variations in CD200 expression across cell types suggest functional heterogeneity.